Search

Your search keyword '"Hamieh, Mohamad"' showing total 175 results
Start Over Author "Hamieh, Mohamad"
175 results on '"Hamieh, Mohamad"'

2. Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.

Author

van der Stegen, Sjoukje, Lindenbergh, Pieter, Petrovic, Roseanna, Xie, Hongyao, Diop, Mame, Alexeeva, Vera, Shi, Yuzhe, Mansilla-Soto, Jorge, Hamieh, Mohamad, Eyquem, Justin, Cabriolu, Annalisa, Wang, Xiuyan, Abujarour, Ramzey, Lee, Tom, Clarke, Raedun, Valamehr, Bahram, Themeli, Maria, Riviere, Isabelle, and Sadelain, Michel

Subjects
Mice, Animals, Humans, T-Lymphocytes, Induced Pluripotent Stem Cells, Receptors, Antigen, T-Cell, CD8 Antigens, Receptors, Chimeric Antigen
Abstract

The production of autologous T cells expressing a chimaeric antigen receptor (CAR) is time-consuming, costly and occasionally unsuccessful. T-cell-derived induced pluripotent stem cells (TiPS) are a promising source for the generation of off-the-shelf CAR T cells, but the in vitro differentiation of TiPS often yields T cells with suboptimal features. Here we show that the premature expression of the T-cell receptor (TCR) or a constitutively expressed CAR in TiPS promotes the acquisition of an innate phenotype, which can be averted by disabling the TCR and relying on the CAR to drive differentiation. Delaying CAR expression and calibrating its signalling strength in TiPS enabled the generation of human TCR- CD8αβ+ CAR T cells that perform similarly to CD8αβ+ CAR T cells from peripheral blood, achieving effective tumour control on systemic administration in a mouse model of leukaemia and without causing graft-versus-host disease. Driving T-cell maturation in TiPS in the absence of a TCR by taking advantage of a CAR may facilitate the large-scale development of potent allogeneic CD8αβ+ T cells for a broad range of immunotherapies.

Published
2022

3. HLA-independent T cell receptors for targeting tumors with low antigen density.

Author

Mansilla-Soto, Jorge, Eyquem, Justin, Haubner, Sascha, Hamieh, Mohamad, Feucht, Judith, Paillon, Noémie, Zucchetti, Andrés, Li, Zhuoning, Sjöstrand, Maria, Lindenbergh, Pieter, Saetersmoen, Michelle, Dobrin, Anton, Maurin, Mathieu, Iyer, Archana, Garcia Angus, Andreina, Miele, Matthew, Zhao, Zeguo, Giavridis, Theodoros, van der Stegen, Sjoukje, Tamzalit, Fella, Rivière, Isabelle, Huse, Morgan, Hendrickson, Ronald, Hivroz, Claire, and Sadelain, Michel

Subjects
Animals, Antigens, CD19, Histocompatibility Antigens, Humans, Immunotherapy, Adoptive, Leukemia, Myeloid, Acute, Mice, Receptors, Antigen, T-Cell, Receptors, Chimeric Antigen, Xenograft Model Antitumor Assays
Abstract

Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tumor escape associated with low target antigen expression is emerging as one potential limitation of their efficacy. Here we edit the TRAC locus in human peripheral blood T cells to engage cell-surface targets through their T cell receptor-CD3 complex reconfigured to utilize the same immunoglobulin heavy and light chains as a matched CAR. We demonstrate that these HLA-independent T cell receptors (HIT receptors) consistently afford high antigen sensitivity and mediate tumor recognition beyond what CD28-based CARs, the most sensitive design to date, can provide. We demonstrate that the functional persistence of HIT T cells can be augmented by constitutive coexpression of CD80 and 4-1BBL. Finally, we validate the increased antigen sensitivity afforded by HIT receptors in xenograft mouse models of B cell leukemia and acute myeloid leukemia, targeting CD19 and CD70, respectively. Overall, HIT receptors are well suited for targeting cell surface antigens of low abundance.

Published
2022

4. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.

Author

Hamieh, Mohamad, Dobrin, Anton, Cabriolu, Annalisa, van der Stegen, Sjoukje, Giavridis, Theodoros, Mansilla-Soto, Jorge, Eyquem, Justin, Zhao, Zeguo, Whitlock, Benjamin, Miele, Matthew, Li, Zhuoning, Cunanan, Kristen, Huse, Morgan, Hendrickson, Ronald, Wang, Xiuyan, Rivière, Isabelle, and Sadelain, Michel

Subjects
4-1BB Ligand, Animals, Antigens, Neoplasm, CD28 Antigens, Cytotoxicity, Immunologic, Female, Immunotherapy, Adoptive, Leukemia, Male, Mice, Mice, Inbred NOD, Neoplasm Recurrence, Local, Receptors, Chimeric Antigen, T-Lymphocytes, Tumor Escape
Abstract

Chimeric antigen receptors (CARs) are synthetic antigen receptors that reprogram T cell specificity, function and persistence1. Patient-derived CAR T cells have demonstrated remarkable efficacy against a range of B-cell malignancies1-3, and the results of early clinical trials suggest activity in multiple myeloma4. Despite high complete response rates, relapses occur in a large fraction of patients; some of these are antigen-negative and others are antigen-low1,2,4-9. Unlike the mechanisms that result in complete and permanent antigen loss6,8,9, those that lead to escape of antigen-low tumours remain unclear. Here, using mouse models of leukaemia, we show that CARs provoke reversible antigen loss through trogocytosis, an active process in which the target antigen is transferred to T cells, thereby decreasing target density on tumour cells and abating T cell activity by promoting fratricide T cell killing and T cell exhaustion. These mechanisms affect both CD28- and 4-1BB-based CARs, albeit differentially, depending on antigen density. These dynamic features can be offset by cooperative killing and combinatorial targeting to augment tumour responses to immunotherapy.

Published
2019

5. Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.

Author

DeSelm, Carl, Palomba, M, Yahalom, Joachim, Hamieh, Mohamad, Eyquem, Justin, Rajasekhar, Vinagolu, and Sadelain, Michel

Subjects
CAR T cell, antigen escape, pancreatic cancer, radiation, sialyl Lewis-A, Animals, Antigens, CD19, Antigens, Neoplasm, CA-19-9 Antigen, Combined Modality Therapy, Disease Models, Animal, Humans, Immunotherapy, Adoptive, Insulin-Secreting Cells, Mice, Oligosaccharides, Pancreatic Neoplasms, Radiation, Radiation Dosage, Receptors, Chimeric Antigen, Sequence Analysis, RNA, TNF-Related Apoptosis-Inducing Ligand
Abstract

CD19 chimeric antigen receptors (CARs) have demonstrated great efficacy against a range of B cell malignancies. However, antigen escape and, more generally, heterogeneous antigen expression pose a challenge to applying CAR therapy to a wide range of cancers. We find that low-dose radiation sensitizes tumor cells to immune rejection by locally activated CAR T cells. In a model of pancreatic adenocarcinoma heterogeneously expressing sialyl Lewis-A (sLeA), we show that not only sLeA+ but also sLeA- tumor cells exposed to low-dose radiation become susceptible to CAR therapy, reducing antigen-negative tumor relapse. RNA sequencing analysis of low-dose radiation-exposed tumors reveals the transcriptional signature of cells highly sensitive to TRAIL-mediated death. We find that sLeA-targeted CAR T cells produce TRAIL upon engaging sLeA+ tumor cells, and eliminate sLeA- tumor cells previously exposed to systemic or local low-dose radiation in a TRAIL-dependent manner. These findings enhance the prospects for successfully applying CAR therapy to heterogeneous solid tumors. Local radiation is integral to many tumors standard of care and can be easily implemented as a CAR conditioning regimen.

Published
2018

6. Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.

Author

Perna, Fabiana, Berman, Samuel, Soni, Rajesh, Mansilla-Soto, Jorge, Eyquem, Justin, Hamieh, Mohamad, Hendrickson, Ronald, Brennan, Cameron, and Sadelain, Michel

Subjects
CAR T cell, acute myeloid leukemia (AML), algorithm, combinatorial strategies, high-throughput annotation, immunotherapy, leukemia, proteomics, surfaceome, target discovery, Antigens, CD19, Cell Line, Tumor, Gene Expression Profiling, Humans, Immunotherapy, Leukemia, Myeloid, Acute, Proteomics, Receptors, Antigen, T-Cell, Recombinant Fusion Proteins, T-Lymphocytes
Abstract

Chimeric antigen receptor (CAR) therapy targeting CD19 has yielded remarkable outcomes in patients with acute lymphoblastic leukemia. To identify potential CAR targets in acute myeloid leukemia (AML), we probed the AML surfaceome for overexpressed molecules with tolerable systemic expression. We integrated large transcriptomics and proteomics datasets from malignant and normal tissues, and developed an algorithm to identify potential targets expressed in leukemia stem cells, but not in normal CD34+CD38- hematopoietic cells, T cells, or vital tissues. As these investigations did not uncover candidate targets with a profile as favorable as CD19, we developed a generalizable combinatorial targeting strategy fulfilling stringent efficacy and safety criteria. Our findings indicate that several target pairings hold great promise for CAR therapy of AML.

Published
2017

7. Immunogenicity of CAR T cells in cancer therapy

Author

Wagner, Dimitrios L., Fritsche, Enrico, Pulsipher, Michael A., Ahmed, Nabil, Hamieh, Mohamad, Hegde, Meenakshi, Ruella, Marco, Savoldo, Barbara, Shah, Nirali N., Turtle, Cameron J., Wayne, Alan S., and Abou-el-Enein, Mohamed

Published
2021
Full Text
View/download PDF

11. Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients

Author

Milcent, Benoit, Josseaume, Nathalie, Riller, Quentin, Giglioli, Ilenia, Rabia, Emilia, Deligne, Claire, Latouche, Jean-Baptiste, Hamieh, Mohamad, Couture, Alexandre, Toutirais, Olivier, Lone, Yu-Chun, Jeger-Madiot, Raphaël, Graff-Dubois, Stéphanie, Amorim, Sandy, Loiseau, Pascale, Toubert, Antoine, Brice, Pauline, Thieblemont, Catherine, Teillaud, Jean-Luc, and Sibéril, Sophie

Published
2019
Full Text
View/download PDF

15. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

Author

Giavridis, Theodoros, van der Stegen, Sjoukje J. C., Eyquem, Justin, Hamieh, Mohamad, Piersigilli, Alessandra, and Sadelain, Michel

Subjects
Laboratory rats -- Models, Gene therapy -- Usage, Corticosteroid drugs -- Dosage and administration, Acute lymphocytic leukemia -- Drug therapy -- Prevention, T cells -- Research, Lymphocytic leukemia, Antigens, Cytokines, Nitrogen oxides, Cancer, Respiratory insufficiency, Preventive medicine, Tumors, Interleukins, Steroids (Organic compounds), Macrophages, Nitric oxide, Biological sciences, Health
Abstract

Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially acute lymphoblastic leukemia (ALL).sup.1. Although a majority of patients will achieve a complete response following a single infusion of CD19-targeted CAR-modified T cells (CD19 CAR T cells).sup.2-4, the broad applicability of this treatment is hampered by severe cytokine release syndrome (CRS), which is characterized by fever, hypotension and respiratory insufficiency associated with elevated serum cytokines, including interleukin-6 (IL-6).sup.2,5. CRS usually occurs within days of T cell infusion at the peak of CAR T cell expansion. In ALL, it is most frequent and more severe in patients with high tumor burden.sup.2-4. CRS may respond to IL-6 receptor blockade but can require further treatment with high dose corticosteroids to curb potentially lethal severity.sup.2-9. Improved therapeutic and preventive treatments require a better understanding of CRS physiopathology, which has so far remained elusive. Here we report a murine model of CRS that develops within 2-3 d of CAR T cell infusion and that is potentially lethal and responsive to IL-6 receptor blockade. We show that its severity is mediated not by CAR T cell-derived cytokines, but by IL-6, IL-1 and nitric oxide (NO) produced by recipient macrophages, which enables new therapeutic interventions. Blocking IL-1 and iNOS prevents CAR T cell-induced cytokine release syndrome., Author(s): Theodoros Giavridis [sup.1] , Sjoukje J. C. van der Stegen [sup.1] , Justin Eyquem [sup.1] , Mohamad Hamieh [sup.1] , Alessandra Piersigilli [sup.2] , Michel Sadelain [sup.1] Author Affiliations: [...]

Published
2018
Full Text
View/download PDF

16. Supplementary Figure 1 from Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy

Author

Maby, Pauline, primary, Tougeron, David, primary, Hamieh, Mohamad, primary, Mlecnik, Bernhard, primary, Kora, Hafid, primary, Bindea, Gabriela, primary, Angell, Helen K., primary, Fredriksen, Tessa, primary, Elie, Nicolas, primary, Fauquembergue, Emilie, primary, Drouet, Aurélie, primary, Leprince, Jérôme, primary, Benichou, Jacques, primary, Mauillon, Jacques, primary, Le Pessot, Florence, primary, Sesboüé, Richard, primary, Tuech, Jean-Jacques, primary, Sabourin, Jean-Christophe, primary, Michel, Pierre, primary, Frébourg, Thierry, primary, Galon, Jérôme, primary, and Latouche, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 2 from Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy

Author

Maby, Pauline, primary, Tougeron, David, primary, Hamieh, Mohamad, primary, Mlecnik, Bernhard, primary, Kora, Hafid, primary, Bindea, Gabriela, primary, Angell, Helen K., primary, Fredriksen, Tessa, primary, Elie, Nicolas, primary, Fauquembergue, Emilie, primary, Drouet, Aurélie, primary, Leprince, Jérôme, primary, Benichou, Jacques, primary, Mauillon, Jacques, primary, Le Pessot, Florence, primary, Sesboüé, Richard, primary, Tuech, Jean-Jacques, primary, Sabourin, Jean-Christophe, primary, Michel, Pierre, primary, Frébourg, Thierry, primary, Galon, Jérôme, primary, and Latouche, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

18. Data from Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy

Author

Maby, Pauline, primary, Tougeron, David, primary, Hamieh, Mohamad, primary, Mlecnik, Bernhard, primary, Kora, Hafid, primary, Bindea, Gabriela, primary, Angell, Helen K., primary, Fredriksen, Tessa, primary, Elie, Nicolas, primary, Fauquembergue, Emilie, primary, Drouet, Aurélie, primary, Leprince, Jérôme, primary, Benichou, Jacques, primary, Mauillon, Jacques, primary, Le Pessot, Florence, primary, Sesboüé, Richard, primary, Tuech, Jean-Jacques, primary, Sabourin, Jean-Christophe, primary, Michel, Pierre, primary, Frébourg, Thierry, primary, Galon, Jérôme, primary, and Latouche, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 3 from Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy

Author

Maby, Pauline, primary, Tougeron, David, primary, Hamieh, Mohamad, primary, Mlecnik, Bernhard, primary, Kora, Hafid, primary, Bindea, Gabriela, primary, Angell, Helen K., primary, Fredriksen, Tessa, primary, Elie, Nicolas, primary, Fauquembergue, Emilie, primary, Drouet, Aurélie, primary, Leprince, Jérôme, primary, Benichou, Jacques, primary, Mauillon, Jacques, primary, Le Pessot, Florence, primary, Sesboüé, Richard, primary, Tuech, Jean-Jacques, primary, Sabourin, Jean-Christophe, primary, Michel, Pierre, primary, Frébourg, Thierry, primary, Galon, Jérôme, primary, and Latouche, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure Legend from Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy

Author

Maby, Pauline, primary, Tougeron, David, primary, Hamieh, Mohamad, primary, Mlecnik, Bernhard, primary, Kora, Hafid, primary, Bindea, Gabriela, primary, Angell, Helen K., primary, Fredriksen, Tessa, primary, Elie, Nicolas, primary, Fauquembergue, Emilie, primary, Drouet, Aurélie, primary, Leprince, Jérôme, primary, Benichou, Jacques, primary, Mauillon, Jacques, primary, Le Pessot, Florence, primary, Sesboüé, Richard, primary, Tuech, Jean-Jacques, primary, Sabourin, Jean-Christophe, primary, Michel, Pierre, primary, Frébourg, Thierry, primary, Galon, Jérôme, primary, and Latouche, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table 1 from Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy

Author

Maby, Pauline, primary, Tougeron, David, primary, Hamieh, Mohamad, primary, Mlecnik, Bernhard, primary, Kora, Hafid, primary, Bindea, Gabriela, primary, Angell, Helen K., primary, Fredriksen, Tessa, primary, Elie, Nicolas, primary, Fauquembergue, Emilie, primary, Drouet, Aurélie, primary, Leprince, Jérôme, primary, Benichou, Jacques, primary, Mauillon, Jacques, primary, Le Pessot, Florence, primary, Sesboüé, Richard, primary, Tuech, Jean-Jacques, primary, Sabourin, Jean-Christophe, primary, Michel, Pierre, primary, Frébourg, Thierry, primary, Galon, Jérôme, primary, and Latouche, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 2 from Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy

Author

Maby, Pauline, primary, Tougeron, David, primary, Hamieh, Mohamad, primary, Mlecnik, Bernhard, primary, Kora, Hafid, primary, Bindea, Gabriela, primary, Angell, Helen K., primary, Fredriksen, Tessa, primary, Elie, Nicolas, primary, Fauquembergue, Emilie, primary, Drouet, Aurélie, primary, Leprince, Jérôme, primary, Benichou, Jacques, primary, Mauillon, Jacques, primary, Le Pessot, Florence, primary, Sesboüé, Richard, primary, Tuech, Jean-Jacques, primary, Sabourin, Jean-Christophe, primary, Michel, Pierre, primary, Frébourg, Thierry, primary, Galon, Jérôme, primary, and Latouche, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

24. CD19 CAR antigen engagement mechanisms and affinity tuning

Author

He, Changhao, primary, Mansilla-Soto, Jorge, additional, Khanra, Nandish, additional, Hamieh, Mohamad, additional, Bustos, Victor, additional, Paquette, Alice J., additional, Garcia Angus, Andreina, additional, Shore, Derek M., additional, Rice, William J., additional, Khelashvili, George, additional, Sadelain, Michel, additional, and Meyerson, Joel R., additional

Published
2023
Full Text
View/download PDF

29. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

Author

Mlecnik, Bernhard, Bindea, Gabriela, Angell, Helen K., Maby, Pauline, Angelova, Mihaela, Tougeron, David, Church, Sarah E., Lafontaine, Lucie, Fischer, Maria, Fredriksen, Tessa, Sasso, Maristella, Bilocq, Amélie M., Kirilovsky, Amos, Obenauf, Anna C., Hamieh, Mohamad, Berger, Anne, Bruneval, Patrick, Tuech, Jean-Jacques, Sabourin, Jean-Christophe, Le Pessot, Florence, Mauillon, Jacques, Rafii, Arash, Laurent-Puig, Pierre, Speicher, Michael R., Trajanoski, Zlatko, Michel, Pierre, Sesboüe, Richard, Frebourg, Thierry, Pagès, Franck, Valge-Archer, Viia, Latouche, Jean-Baptiste, and Galon, Jérôme

Published
2016
Full Text
View/download PDF

30. 132 HLA-independent T cell receptors effectively target low abundance antigens

Author

Mansilla-Soto, Jorge, primary, Eyquem, Justin, additional, Haubner, Sascha, additional, Hamieh, Mohamad, additional, Feucht, Judith, additional, Paillon, Noémie, additional, Zucchetti, Andres, additional, Li, Zhuoning, additional, Sjöstrand, Maria, additional, Lindenbergh, Pieter, additional, Saetersmoen, Michelle, additional, Maurin, Mathieu, additional, Iyer, Archana, additional, Dobrin, Anton, additional, Angus, Andreina Garcia, additional, Miele, Matthew, additional, Zhao, Zeguo, additional, Giavridis, Theodoros, additional, Stegen, Sjoukje van der, additional, Tamzalit, Fella, additional, Huse, Morgan, additional, Hendrickson, Ronald, additional, Hivroz, Claire, additional, and Sadelain, Michel, additional

Published
2021
Full Text
View/download PDF

31. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy

Author

Hamieh, Mohamad, primary, Chatillon, Jean-François, additional, Dupel, Estelle, additional, Bayeux, Florence, additional, Fauquembergue, Emilie, additional, Maby, Pauline, additional, Drouet, Aurelie, additional, Duval-Modeste, Anne-Bénédicte, additional, Adriouch, Sahil, additional, Boyer, Olivier, additional, and Latouche, Jean-Baptiste, additional

Published
2021
Full Text
View/download PDF

34. Study of genetic mutations and dynamic spread of SARS-CoV-2 pandemic and prediction of its evolution according to the SIR model

Author

Hamieh Mohamad, Doumit Mary, Toufaily Joumana, and Tayssir Hamieh

Subjects
body regions, FOS: Biological sciences, fungi, Populations and Evolution (q-bio.PE), food and beverages, Quantitative Biology - Populations and Evolution
Abstract

In this work, we aim to study that the dynamics behavior for cumulative number of SARS-CoV-2 pandemic can provide information on the overall behavior of the spread over daily time.The cumulative data can be synthesized in an empirical form obtained from a Susceptible-Infected-Recovered (SIR) model previously studied on a Euclidean network. From the study we carried out, we can conclude that the SIR model on the Euclidean network can reproduce data from several countries with a deviation of precision for given parameter values. This gives an insight into the different agents that influence the behavior of SARS-CoV-2 especially during the virus mutation period. We are thus trying to analyze the effect of genetic mutations in different countries, and how a specific mutation can make the virus more contagious., 13 pages, 3 figures

Published
2020

39. Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Author

Gilardin, Laurent, Delignat, Sandrine, Peyron, Ivan, Ing, Mathieu, Lone, Yu-Chun, Gangadharan, Bagirath, Michard, Baptiste, Kherabi, Yousra, Sharma, Meenu, Pashov, Anastas, Toutirais, Olivier, Loiseau, Pascale, Veyradier, Agnès, Kaveri, Srini, Maillere, Bernard, Coppo, Paul, Lacroix-Desmazes, Sébastien, Chatillon, Jean-François, Hamieh, Mohamad, Bayeux, Florence, Abasq, Claire, Fauquembergue, Emilie, Drouet, Aurélie, Guisier, Florian, Latouche, Jean-Baptiste, Musette, Philippe, Coignard-Biehler, Hélène, Mahlaoui, Nizar, Pilmis, Benoit, Barlogis, Vincent, Brosselin, Pauline, de Vergnes, Nathalie, Debré, Marianne, Malphettes, Marion, Frange, Pierre, Catherinot, Emilie, Pellier, Isabelle, Durieu, Isabelle, Perlat, Antoinette, Royer, Bruno, Le Quellec, Alain, Jeziorski, Eric, Fischer, Alain, Lortholary, Olivier, Aaron+, Laurent, Adoue, Daniel, Aguilar, Claire, Aladjidi, Nathalie, Alcaïs, Alexandre, Amoura, Zahir, Arlet, Philippe, Armari-Alla, Corinne, Bader-Meunier, Brigitte, Bayart, Sophie, Bienvenu, Boris, Blanche, Stéphane, Bodet, Damien, Bonnotte, Bernard, Borie, Raphael, Boutard, Patrick, Briandet, Claire, Brion, Jean-Paul, Brouard, Jacques, Cohen-Beaussant, Sarah, Costes, Laurence, Couderc, Louis-Jean, Cougoul, Pierre, Courteille, Virginie, de Saint Basile, Geneviève, Devoldere, Catherine, Deville, Anne, Donadieu, Jean, Doré, Eric, Dulieu, Fabienne, Edan, Christine, Entz-Werlé, Natacha, Fieschi, Claire, Forestier, Amandine, Fouyssac, Fanny, Gajdos, Vincent, Galicier, Lionel, Gandemer, Virginie, Gardembas, Martine, Gaud, Catherine, Guillerm, Gaelle, Hachulla, Eric, Hamidou, Mohamed, Hermine, Olivier, Hoarau, Cyrille, Humbert, Sebastien, Jaccard, Arnaud, Jacquot, Serge, Jais, Jean-Philippe, Jaussaud, Roland, Jeandel, Pierre-Yves, Kebaili, Kamila, Korganow, Anne-Sophie, Lambotte, Olivier, Lanternier, Fanny, Larroche, Claire, Lascaux, Anne-Sophie, Le Moigne, Emmanuelle, Le Moing, Vincent, Lebranchu, Yvon, Lecuit, Marc, Lefèvre, Guillaume, Lemal, Richard, Te, Valérie Li Thiao, Marie-Cardine, Aude, Silva, Nicolas Martin, Masseau, Agathe, Massot, Christian, Mazingue, Françoise, Merlin, Etienne, Monlibert, Béatrice, Monpoux, Fabrice, Moshous, Despina, Mouthon, Luc, Munzer, Martine, Neven, Bénédicte, Nove-Josserand, Raphaëlle, Oksenhendler, Eric, Ouachée-Chardin, Marie, Oudot, Caroline, Pagnier, Anne, Pasquali, Jean-Louis, Pasquet, Marlène, Perel, Yves, Picard, Capucine, Piguet, Christophe, Plantaz, Dominique, Provot, Johan, Quartier, Pierre, Rieux-Laucat, Frédéric, Roger, Pierre-Marie, Rohrlich, Pierre-Simon, Rubié, Hervé, Salle, Valéry, Sarrot-Reynauld, Françoise, Servettaz, Amélie, Stephan, Jean-Louis, Schleinitz, Nicolas, Suarez, Felipe, Swiader, Laure, Taque, Sophie, Thomas, Caroline, Tournilhac, Olivier, Thumerelle, Caroline, Tron, François, Viallard, Jean-François, Roux, Clément, Tifratene, K, Socie, G., Galambrun, C., Bertrand, Yves, Rialland, F., Jubert, C, Pochon, C, Paillard, C., Sirvent, A., Nelken, B., Vannier, Jean-Pierre, Freycon, C, Beguin, Y, Raus, N, Yakoub-Agha, I., Mohty, M., Dalle, J-H, Michel, Gérard, Pradier, C., Peffault de Latour, R., Rohrlich, P-S, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Greffes d'Epitheliums et Regulation de l'Activation Lymphocytaire, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Les Hôptaux universitaires de Strasbourg (HUS), CHU Strasbourg, Institut Stephan Angeloff, Réseau International des Instituts Pasteur (RIIP), Immunogénétique humaine, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hématologie Biologique [Béclère], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département d'Ingénierie et d'Etudes des Protéines, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Service de dermatologie (Dermato - BREST), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Génétique du cancer et des maladies neuropsychiatriques (GMFC), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hématologie pédiatrique, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'immuno-hématologie pédiatrique [CHU Necker], Service d'Immunopathologie [Hôpital Saint-Louis, Paris], Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Unité d'Immunologie Hématologie et Rhumatologie Pédiatrique [Necker, Paris], Hôpital Foch [Suresnes], Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Médecine Interne - Centre Hospitalier Lyon Sud, Hospices Civils de Lyon (HCL)-Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Service de Médecine interne et immunologie clinique [Rennes] = internal medicine and clinical immunology [Rennes], CHU Pontchaillou [Rennes], CHU Amiens-Picardie, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Collège de France - Chaire Médecine expérimentale (A. Fischer), Collège de France (CdF (institution)), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Département de Pédiatrie et maladies infectieuses [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Service d'Hémato-oncologie Pédiatrique, CHU Bordeaux [Bordeaux]-Hôpital Pellegrin, Génétique Humaine des Maladies Infectieuses (Inserm U980), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service Médecine Interne et immunologie clinique [CHU Toulouse], Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital de la Tronche, Département d'Immunologie, hématologie et rhumatologie pédiatriques [Hôpital Necker-Enfants malades - APHP], Hématogoie pédiatrique, hôpital Sud, Laboratoire de Mathématiques Nicolas Oresme (LMNO), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Physiopathologie et Epidémiologie des Maladies Respiratoires (PHERE (UMR_S_1152 / U1152)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Pédiatrie Enfants - Hématologie Oncologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service des Maladies Infectieuses, CHU Grenoble, Service de Pédiatrie Médicale [Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Nutrition et Neurobiologie intégrée (NutriNeuro), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA)-Université Sciences et Technologies - Bordeaux 1 (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique, Developpement Normal et Pathologique du Système Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'Hémato-oncologie Pédiatrique [CHU Nice], Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Trousseau [APHP], Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Département d'Oncologie Pédiatrique [CHU Hautepierre, Strasbourg], Hôpital de Hautepierre [Strasbourg], Immunologie clinique [CHU St-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service d'Hématologie et d'Oncologie Pédiatrique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine de l'enfant et de l'adolescent [CHU Rennes], Apoptosis and Tumor Progression (CRCINA-ÉQUIPE 9), Service Hématologie, Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de médecine interne [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Cellules Dendritiques, Immunomodulation et Greffes, Université de Tours (UT), Ecole Polytechnique Fédérale de Lausanne (EPFL), Physiologie Moléculaire de la Réponse Immune et des Lymphoproliférations (PMRIL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Physiopathologie et biothérapies des maladies inflammatoires et autoimmunes, Service d'informatique médicale et biostatistiques [CHU Necker], Université de Reims Champagne-Ardenne (URCA), Institut d’Hémato-Oncologie Pédiatrique, Immunologie et chimie thérapeutiques (ICT), Cancéropôle du Grand Est-Centre National de la Recherche Scientifique (CNRS), service de Médecine Interne et d'Immunologie Clinique [AP-HP Hôpital Bicêtre], Université Paris-Sud - Paris 11 (UP11)-Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris (AP-HP), Internal Medicine, Paris, Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, Catalysis, Synthesis of Biomolecules and Sustainable Development (CSB2D), Centre National de la Recherche Scientifique (CNRS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Unité de Biostatistique et de Recherche Clinique (UBRC), Dept of Physiology, McGill University = Université McGill [Montréal, Canada], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut Jean Godinot [Reims], UNICANCER, Service d'Immunopathologie Clinique, Service d'hématologie et immunologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Service de Pédiatrie médicale - Spécialités médicales [CHU Limoges], CHU Limoges, Service Immuno Hémato-Onco Pédiatrique, Sercice Hématologie, immunologie et oncologie pédiatrique [CHU Toulouse], Pôle Enfants [CHU Toulouse], Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service Hématologie Infantile, Immunogenetics of pediatric autoimmune diseases (Equipe Inserm U1163), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Département de Médecine Interne, Immunologie clinique et maladies infectieuses [CHU Reims], Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'Hématologie et d'Oncologie pédiatrique, Service d'hématologie clinique, Hôpital Hôtel-Dieu [Paris], Service de pneumologie pédiatrique, Hôpital Jeanne de Flandre [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Protéines de défense des réponses immune et inflammatoire : identification, régulation et rôles physiopathologiques, Médecine Interne, CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de Pediatrie Debrousse, Hôpital Debrousse, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de Combustion, Aérothermique, Réactivité et Environnement (ICARE), Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)-Institut des Sciences de l'Ingénierie et des Systèmes (INSIS - CNRS), Service d'Hématologie et d'Oncologie Médicale, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Service d'hémato-immuno-oncologie pédiatrique [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Etablissement français du sang [Poitiers] (EFS), Public Health Department, Hôpital de l'Archet, Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7), École pratique des hautes études (EPHE)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Antoine Béclère, Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Université Paris Diderot - Paris 7 (UPD7)-CHU Saint Louis [APHP], CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Innate immunity and Immunotherapy (CRCINA - Département INCIT - Equipe 7), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Service de médecine interne, Hôpital Universitaire d'Amiens, CHU Toulouse [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Service de médecine interne, hôpital Purpan, Hôpital Sud, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (HOTE GREFFON), Université de Franche-Comté (UFC)-Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté])-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition et Neurobiologie intégrée (NutriNeur0), Ecole nationale supérieure de chimie, biologie et physique-Institut Polytechnique de Bordeaux-Université Sciences et Technologies - Bordeaux 1-Institut National de la Recherche Agronomique (INRA)-Université Bordeaux Segalen - Bordeaux 2, Service d’oncologie hématologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], CIC - Clermont Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine de l'enfant et de l'adolescent, CHU Pontchaillou [Rennes]-Hôpital Sud, Apoptose et Progression tumorale (CRCNA / Equipe 9), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche en Santé de l'Université de Nantes (IRS-UN), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Morvan [Brest], Lille Inflammation Research International Center (LIRIC), Université de Tours, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), CHU Toulouse [Toulouse]-Hôpital de Rangueil, Institute of Chemistry for Life and Health Sciences (i-CLEHS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias - Clermont Auvergne (CHELTER), Université Clermont Auvergne (UCA), McGill University, Institut Jean Godinot, CRLCC Jean Godinot, Université Paris Diderot - Paris 7 (UPD7)-Hôpital Robert Debré-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Hématologie pédiatrique, Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA), Unité d'Hémato-Oncologie, Hôpital des Enfants, CHU Saint-Etienne, Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)-Institut des Sciences de l'Ingénierie et des Systèmes (INSIS), CHU Saint-Antoine [APHP], École pratique des hautes études (EPHE), Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Chaire Médecine expérimentale (A. Fischer), Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA)-Université Sciences et Technologies - Bordeaux 1-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique, Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), CHU Pontchaillou [Rennes]-hôpital Sud, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Université Paris Diderot - Paris 7 (UPD7)-Hôpital Robert Debré-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)

Subjects
Oncology, medicine.medical_specialty, Palliative care, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Hematopoietic stem cell transplantation, Donor lymphocyte infusion, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Transplantation, Homologous, Treatment Failure, Child, ComputingMilieux_MISCELLANEOUS, Retrospective Studies, Transplantation, Acute leukemia, Chemotherapy, Leukemia, business.industry, Palliative Care, Hematopoietic Stem Cell Transplantation, Hematology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Donor Lymphocytes, Leukemia, Biphenotypic, Acute, 3. Good health, Surgery, Survival Rate, Leukemia, Myeloid, Acute, Treatment Outcome, Lymphocyte Transfusion, 030220 oncology & carcinogenesis, Acute Disease, Disease Progression, [SDV.IMM]Life Sciences [q-bio]/Immunology, business, 030215 immunology
Abstract

Allogeneic hematopoietic stem cell transplantation (SCT) contributes to improved outcome in childhood acute leukemia (AL). However, therapeutic options are poorly defined in the case of post-transplantation relapse. We aimed to compare treatment strategies in 334 consecutive children with acute leukemia relapse or progression after SCT in a recent 10-year period. Data could be analyzed in 288 patients (157 ALL, 123 AML and 8 biphenotypic AL) with a median age of 8.16 years at transplantation. The median delay from first SCT to relapse or progression was 182 days. The treatment consisted of chemotherapy alone (n=108), chemotherapy followed by second SCT (n=70), supportive/palliative care (n=67), combination of chemotherapy and donor lymphocyte infusion (DLI; n=30), or isolated reinfusion of donor lymphocytes (DLI; n=13). The median OS duration after relapse was 164 days and differed according to therapy: DLI after chemotherapy=385 days, second allograft=391 days, chemotherapy=174 days, DLI alone=140 days, palliative care=43 days. A second SCT or a combination of chemotherapy and DLI yielded similar outcome (hazard ratio (HR)=0.85, P=0.53) unlike chemotherapy alone (HR=1.43 P=0.04), palliative care (HR=4.24, P

Published
2017

43. The ADAMTS13 1239–1253 peptide is a dominant HLA-DR1-restricted CD4 + T-cell epitope

Author

Gilardin, Laurent, primary, Delignat, Sandrine, additional, Peyron, Ivan, additional, Ing, Mathieu, additional, Lone, Yu-Chun, additional, Gangadharan, Bagirath, additional, Michard, Baptiste, additional, Kherabi, Yousra, additional, Sharma, Meenu, additional, Pashov, Anastas, additional, Latouche, Jean-Baptiste, additional, Hamieh, Mohamad, additional, Toutirais, Olivier, additional, Loiseau, Pascale, additional, Galicier, Lionel, additional, Veyradier, Agnès, additional, Kaveri, Srini, additional, Maillère, Bernard, additional, Coppo, Paul, additional, and Lacroix-Desmazes, Sébastien, additional

Published
2017
Full Text
View/download PDF

44. Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice

Author

Rangan, Laurie, primary, Galaine, Jeanne, additional, Boidot, Romain, additional, Hamieh, Mohamad, additional, Dosset, Magalie, additional, Francoual, Julie, additional, Beziaud, Laurent, additional, Pallandre, Jean-René, additional, Joseph, Elodie Lauret Marie, additional, Asgarova, Afag, additional, Borg, Christophe, additional, Al Saati, Talal, additional, Godet, Yann, additional, Latouche, Jean Baptiste, additional, Valmary-Degano, Séverine, additional, and Adotévi, Olivier, additional

Published
2017
Full Text
View/download PDF

46. Direct Toll-Like Receptor 8 signaling increases the functional avidity of human CD8+ T lymphocytes generated for adoptive T cell therapy strategies

Author

Chatillon, Jean-François, Hamieh, Mohamad, Bayeux, Florence, Abasq, Claire, Fauquembergue, Emilie, Drouet, Aurélie, Guisier, Florian, Latouche, Jean-Baptiste, Musette, Philippe, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), CHU Rouen, Génétique du cancer et des maladies neuropsychiatriques (GMFC), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Service de Dermatologie [Rouen], and Hôpital Charles Nicolle [Rouen]-CHU Rouen

Subjects
[SDV]Life Sciences [q-bio], melanoma, Toll-Like receptors, chemical and pharmacologic phenomena, immunotherapy, cytotoxic T lymphocytes, functional avidity
Abstract

International audience; Adoptive transfer of in vitro activated and expanded antigen-specific cytotoxic T lymphocytes (CTLs) is a promising therapeutic strategy for infectious diseases and cancers. Obtaining in vitro a sufficient amount of highly specific cytotoxic cells and capable of retaining cytotoxic activity in vivo remains problematic. We studied the role of Toll-Like Receptor-8 (TLR8) engagement on peripheral CTLs activated with melanoma antigen MART-1-expressing artificial antigen-presenting cells (AAPCs). After a 3-week co-culture, 3–27% of specific CTLs were consistently obtained. CTLs expressed TLR8 in the intracellular compartment and at the cell surface. Specific CTLs activated with a TLR8 agonist (CL075) 24 h before the end of the culture displayed neither any change in their production levels of molecules involved in cytotoxicity (IFN-γ, Granzyme B, and TNF-α) nor major significant change in their cell surface phenotype. However, these TLR8-stimulated lymphocytes displayed increased cytotoxic activity against specific peptide-pulsed target cells related to an increase in specific anti-melanoma CTL functional avidity. TLR8 engagement on CTLs could, therefore, be useful in different immunotherapy strategies.

Published
2015

47. Ligne de transmission multi-accès dans un contexte de réseau sur puce

Author

Hamieh, Mohamad, Ariaudo, Myriam, Quintanel, Sébastien, Louët, Yves, Ariaudo, Myriam, Ingénierie Numérique et Sécurité - Réseau sur puce basé sur des interconnexions RF reconfigurable à la demande - - WiNoCoD2012 - ANR-12-INSE-0004 - INS - VALID, ASTRE [Cergy-Pontoise], Equipes Traitement de l'Information et Systèmes (ETIS - UMR 8051), Ecole Nationale Supérieure de l'Electronique et de ses Applications (ENSEA)-Centre National de la Recherche Scientifique (CNRS)-CY Cergy Paris Université (CY)-Ecole Nationale Supérieure de l'Electronique et de ses Applications (ENSEA)-Centre National de la Recherche Scientifique (CNRS)-CY Cergy Paris Université (CY), Ecole Nationale Supérieure de l'Electronique et de ses Applications (ENSEA)-Centre National de la Recherche Scientifique (CNRS)-CY Cergy Paris Université (CY), Institut d'Électronique et des Technologies du numéRique (IETR), Université de Nantes (UN)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS), ANR-12-INSE-0004,WiNoCoD,Réseau sur puce basé sur des interconnexions RF reconfigurable à la demande(2012), Nantes Université (NU)-Université de Rennes 1 (UR1), Université de Nantes (UN)-Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), and Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)

Subjects
ComputingMilieux_MISCELLANEOUS, [SPI.TRON] Engineering Sciences [physics]/Electronics, [SPI.TRON]Engineering Sciences [physics]/Electronics
Abstract

National audience

Published
2015

48. A new interconnect method for radio frequency intra‐chip communications using transistors‐based distributed access.

Author

Hamieh, Mohamad, Quintanel, Sébastien, Ariaudo, Myriam, and Louët, Yves

Subjects
*RADIO frequency identification systems, *ELECTRIC lines, *BICMOS logic circuits, *TRANSISTORS, *CAPACITIVE sensors
Abstract

This paper presents a new radio frequency channel access method to a radio frequency (RF) interconnect for intra‐chip communications. The method overcomes the undesired effects that come from multiple connections in classical methods. It is based on an active access, through transistors associated in a distributed topology. This leads to better properties in terms of reflection and transmission coefficients along the transmission line. This approach is validated by making a deep comparison with the basic existing access methods (eg, direct and capacitive). Measurements on a test circuit using the 0.25 μm SiGe BiCMOS technology confirm the good performance of the proposed access. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

49. WiNoCoD : Un réseau d'interconnexion hiérarchique RF pour les MPSoC

Author

Brière, Alexandre, Denoulet, Julien, Pinna, Andrea, Granado, Bertrand, Pêcheux, François, Garda, Patrick, Ariaudo, Myriam, Drillet, Frédéric, Duperrier, Cédric, Hamieh, Mohamad, Quintanel, Sébastien, Romain, Olivier, Zerioul, Lounis, Louët, Yves, Moy, Christophe, Unlu, Eren, Bourdel, Emmanuelle, Systèmes Electroniques (SYEL), Laboratoire d'Informatique de Paris 6 (LIP6), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Circuits Intégrés Numériques et Analogiques (CIAN), ASTRE [Cergy-Pontoise], Equipes Traitement de l'Information et Systèmes (ETIS - UMR 8051), Ecole Nationale Supérieure de l'Electronique et de ses Applications (ENSEA)-Centre National de la Recherche Scientifique (CNRS)-CY Cergy Paris Université (CY)-Ecole Nationale Supérieure de l'Electronique et de ses Applications (ENSEA)-Centre National de la Recherche Scientifique (CNRS)-CY Cergy Paris Université (CY), Institut d'Électronique et des Technologies du numéRique (IETR), Nantes Université (NU)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS), ANR-12-INSE-0004,WiNoCoD,Réseau sur puce basé sur des interconnexions RF reconfigurable à la demande(2012), Université de Nantes (UN)-Université de Rennes 1 (UR1), Brière, Alexandre, Ingénierie Numérique et Sécurité - Réseau sur puce basé sur des interconnexions RF reconfigurable à la demande - - WiNoCoD2012 - ANR-12-INSE-0004 - INS - VALID, Université de Nantes (UN)-Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), and Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)

Subjects
many cœur, [INFO.INFO-AR]Computer Science [cs]/Hardware Architecture [cs.AR], [INFO.INFO-AR] Computer Science [cs]/Hardware Architecture [cs.AR], multi cœur, WiNoCoD, RF, reconfigurable, MPSoC, NoC, hiérarchique
Abstract

International audience; La multiplication du nombre de cœurs de calcul présents sur les puces va de pair avec une augmentation des besoins en communication. C'est pour palier à ce problème que nous présentons dans cette article un réseau d'interconnexion sur puce utilisant la RF. Nous présentons les raisons du choix de la RF par rapport aux autres nouvelles technologies du domaine que sont l'optique et la 3D, l'architecture détaillée de ce réseau et d'une puce le mettant en œuvre ainsi que l'évaluation de sa faisabilité et de ses performances. Un des avantages potentiels de ce réseau d'interconnexion RF est la possibilité de faire du broadcast à faible coût, ce qui ouvre de nouvelles perspectives notamment en terme de gestion de la cohérence mémoire.

Published
2014

50. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts

Author

Feucht, Judith, primary, Kayser, Simone, additional, Gorodezki, David, additional, Hamieh, Mohamad, additional, Döring, Michaela, additional, Blaeschke, Franziska, additional, Schlegel, Patrick, additional, Bösmüller, Hans, additional, Quintanilla-Fend, Leticia, additional, Ebinger, Martin, additional, Lang, Peter, additional, Handgretinger, Rupert, additional, and Feuchtinger, Tobias, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results